COSENTYXHCP.COM

For adults with moderate to severe plaque psoriasis and active psoriatic arthritis
In the ERASURE study at week 12, 82% of adult patients with moderate to severe plaque psoriasis in the COSENTYX 300-mg arm (n=245) achieved a PASI 75 response and 65% of patients achieved IGA 0 or 1 vs 4% and 2% in the placebo group (n=248), respectively. In the FIXTURE study at week 12, 76% of adult patients with moderate to severe plaque psoriasis in the COSENTYX 300-mg arm (n=327) achieved a PASI 75 response and 62% achieved IGA 0 or 1 vs 5% and 3% in the placebo group (n=326), respectively. In the FUTURE 2 study, for adults with active psoriatic arthritis treated with COSENTYX 300 mg (n=100), 150 mg (n=100), or placebo (n=98), ACR20 response at week 24 was 54%, 51%, and 15%, respectively. In the ERASURE (N=738) and FIXTURE (N=1306) studies, among the subjects who chose to participate (39%) in assessments of patient-reported outcomes, improvements in signs and symptoms related to itching, pain, and scaling at week 12 compared with placebo were observed using the Psoriasis Symptom Diary©.ACR, American College of Rheumatology; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.

Reference: Cosentyx [prescribing information].
East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2021.

Discover Experience That Matters
Learn more about the extensive clinical data in adults supporting the biologic COSENTYX that is widely prescribed across 3 indications in the US.
Your patients can get real support and personal solutions with COSENTYX CONNECT. Learn more.
US, United States.
View the Complete COSENTYX Approach video
Immerse yourself in the Complete COSENTYX Approach through a video that demonstrates how COSENTYX can help your patients Look Better, Move Better, and Feel Better. For adults with moderate to severe plaque psoriasis and active PsA, choose Experience That Matters.
PsA, psoriatic arthritis.
MINIMIZE
For adults with moderate to severe plaque psoriasis and active psoriatic arthritis
In the ERASURE study at week 12, 82% of adult patients with moderate to severe plaque psoriasis in the COSENTYX 300-mg arm (n=245) achieved a PASI 75 response and 65% of patients achieved IGA 0 or 1 vs 4% and 2% in the placebo group (n=248), respectively. In the FIXTURE study at week 12, 76% of adult patients with moderate to severe plaque psoriasis in the COSENTYX 300-mg arm (n=327) achieved a PASI 75 response and 62% achieved IGA 0 or 1 vs 5% and 3% in the placebo group (n=326), respectively. In the FUTURE 2 study, for adults with active psoriatic arthritis treated with COSENTYX 300 mg (n=100), 150 mg (n=100), or placebo (n=98), ACR20 response at week 24 was 54%, 51%, and 15%, respectively. In the ERASURE (N=738) and FIXTURE (N=1306) studies, among the subjects who chose to participate (39%) in assessments of patient-reported outcomes, improvements in signs and symptoms related to itching, pain, and scaling at week 12 compared with placebo were observed using the Psoriasis Symptom Diary©.
ACR, American College of Rheumatology; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.
Reference: Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2021.